Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bafna PharmaceuticalsNSE:BAFNAPH +1.99%58 3-Year Book Growth Rate is 9.40% as of Jun. 2026, which is at its 10-year median of 9.40. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 58/100 and a GF Value™ of ₹86.03 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 912 Drug Manufacturers companies, Bafna Pharmaceuticals ranks better than 68.2% on this metric.
During the past 12 months, Bafna Pharmaceuticals's average Book Value per Share Growth Rate was 13.40% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 9.40% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 11.10% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 7.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Bafna Pharmaceuticals was 48.10% per year. The lowest was -36.20% per year. And the median was 9.40% per year.
Bafna Pharmaceuticals (NSE:BAFNAPH) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Bafna Pharmaceuticals 3-Year Book Growth Rate Related Terms
NSE:BAFNAPH vs ZTS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's 3-Year Book Growth Rate falls into.
Bafna Pharmaceuticals 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 9.40% mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a 3-Year Book Growth Rate of 9.40% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Bafna Pharmaceuticals and its competitors. This is near median its historical median of 9.40. According to the industry distribution chart, Bafna Pharmaceuticals ranks #290 out of 912 companies in the Drug Manufacturers industry, placing it in the top 31.8%.
Is Bafna Pharmaceuticals' 3-Year Book Growth Rate too high?
Bafna Pharmaceuticals' current 3-Year Book Growth Rate of 9.40% is near median its 10-year median of 9.40. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Bafna Pharmaceuticals' value of 9.40% is 104.3% above this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #290 out of 912 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #290 out of 912 companies for 3-Year Book Growth Rate. This puts Bafna Pharmaceuticals in the upper half of its industry. The industry median 3-Year Book Growth Rate is 4.60. Bafna Pharmaceuticals' value of 9.40% is 104.3% above this benchmark. While the company's 10-year median is 9.40 vs. the industry median of 4.60, Bafna Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 912 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current 3-Year Book Growth Rate of 9.40% is 104.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current 3-Year Book Growth Rate is 9.40%, which is near median its own 10-year median of 9.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹86.03, compared to a current price of ₹317.20 — trading 268.7% above its estimated fair value. The current 3-Year Book Growth Rate is 9.40%, which is near median its 10-year median of 9.40 and 104.3% above the Drug Manufacturers industry median of 4.60. Bafna Pharmaceuticals' overall GF Score™ is 58/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current 3-Year Book Growth Rate is 9.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹317.20 is trading 268.7% above its estimated GF Value™ of ₹86.03.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
3-Year Book Growth Rate: 9.40% (near median its 10-year median of 9.40)
GF Value™: ₹86.03 vs. price of ₹317.20 (268.7% above fair value)
Industry Position: 104.3% above the Drug Manufacturers median (#290 of 912)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
58GF Score
Get the complete analysis for NSE:BAFNAPH
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
